WeightWatchers: 2026 Q1 Earnings Update
$WW
Weightwatchers reported 2026 Q1 earnings on May 7 before the market opened. In the days leading up to the earnings report, the share price was on a modest recovery from a low of $9 to almost $12. However, the share price then opened -22.5% lower, before closing at $10.20 into the weekend.
Headline numbers
Revenue $168.3M, down -10% YoY, but 6% above consensus of $158.5M.
Mix towards clinical: Clinical subscription revenue +32% YoY; behavioral subscription revenue -17% YoY.
Clinical subscribers: 197,000, up 51% sequentially and up 46% YoY.
Behavioral subscribers: 2.5 million, down -25% YoY. The legacy business is still melting faster than the company can fully offset.
Adjusted EBITDA: negative $1.8 million, but Q1 is seasonally the worst quarter in Q1.
Guidance: Management reaffirmed $105 million to $115 million of 2026 adjusted EBITDA, implying a large back-half profit recovery
Q1 beat revenue expectations, but earnings were weak because marketing was deliberately front-loaded around Med+ awareness and the Wegovy pill launch. Management said Q1 is normally the peak marketing and cash-usage quarter, with revenue recognized over the rest of the year.
Mix is improving significantly, with clinical going from 16% of 2025 revenue toward 25-30% of 2026 revenue, and adjusted gross margin holding at 73.6% despite clinical's higher cost to serve.
One-off and timing items:
lapping the May 2025 wind-down of compounded semaglutide is a $20M opening headwind for 2026, with about 20% of those members retained.
FX added $4M and Q1 had one fewer day than Q1 2025.
The good part is clinical and Core+ are growing. The Q1 EBITDA loss understates run-rate due to marketing front-loading, and the full-year guide is the better anchor. The bad part is that the core behavioral base is still shrinking sharply.
KPI’s and Key Drivers
Volume: Clinical subscriber volume drove the upside. Clinical subscribers reached 197,000, up 51% sequentially. Med+ benefited from the Wegovy pill launch and broader GLP-1 affordability.
Core+ also returned to growth with 537,000 subscribers, up 6% YoY.Core+ benefited from virtual workshops, registered dietitian and physician-led sessions, GLP-1 success programs, and menopause programming.
Behavioral subscribers fell to 2.5 million, down 25% YoY.
Price and mix: ARPU rose 13% YoY to $20.59. Clinical ARPU is over 4x behavioral ARPU, and Core+ ARPU is nearly 2x Core ARPU.
Costs: Marketing expense was $93 million in Q1, intentionally front-loaded, producing a 10-point lift in awareness that WW offers GLP-1. Adjusted SG&A was 15% of revenue, helped by the headquarters lease exit. Product development was 5% of revenue.
Internal mobility: 20,000+ behavioral members upgraded to clinical in Q1, and roughly 20% of Core+ sign-ups were upgrades from Core. New customer acquisition: 50% of clinical members joining were new to WW.
Retention and engagement: Management said Med+ members who regularly engaged with the GLP-1 success program lost 29.1% more body weight at 12 months than those without structured behavioral support. They also cited 19.4% real-world weight loss at 12 months on the clinical platform. This is supportive for the employer and payer pitch as WW needs proof that it is more than a prescription access layer.
Capital allocation
WW ended Q1 with $121 million of cash, down from $160 million at year-end. The cash decline reflected adjusted EBITDA loss, $12 million of quarterly term loan interest, $6 million of capex, and marketing payment timing.
A personal highlight: In the last weeks WW’s term loan traded significantly below par. I suggested to WW investor relations that they should see if they can buy back their debt at a discount. Just 12 days later management acted and announced to buy back some debt at a discount.
In the earnings call, WW clarified to use $37 million of cash in Q2 to reduce term loan principal by $42 million, including a voluntary solicitation at 68.5% of par. Management expects this to reduce annualized interest expense by about $4 million based on a 10.5% term loan rate.
Management demonstrated they are acting like owners. Retiring $42M of debt for $37M cash is an immediate ~$5M gain plus the coupon savings, and the CFO signaled openness to more opportunistic paydowns.
Guidance and setup
Management reaffirmed 2026 guidance:
Management expects sequential clinical subscriber growth through the year, but at a much lower pace than Q1 because Q1 benefited from seasonality, higher marketing, and the Wegovy pill launch. Behavioral declines should remain broadly similar to Q1, but mix shift toward Core+ should support ARPU.
What the market may misunderstand
Overall, this print was very much in line with short term expectations, especially since management had re-confirmed revenue and EBITDA guidance twice before the print. As such, the immediate market reaction was a bit surprising, perhaps some reasons what Mr. Market may be underappreciating for now:
The -10% headline revenue masks the positive mix shift. Clinical +32% and behavioral -17% shows the direction of where the puck is going in the next years.
The Q1 EBITDA loss is consistent with seasonal marketing front-loading. The reaffirmed full-year guide implies $107-117M of EBITDA across Q2-Q4.
Retiring term loan at 68.5% of par with a 10.5% coupon is high-IRR capital allocation that does not flow through EBITDA.
Lapping compounded semaglutide will create revenue acceleration in H2 from easier comps.
My read is that the market may still be overly focused on the behavioral user decline.
Below, I provide my updated estimate of owner earnings, and how the earnings updated impacted my long term view on WW.
Valuation and Positioning
